Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
avacopan + cyclophosphamide + rituximab + glucocorticoids
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Avacopan (CCX168) is an oral small-molecule antagonist of the complement C5a receptor 1 (C5aR1). It is used in combination with standard immunosuppressive therapies—specifically cyclophosphamide or rituximab, and glucocorticoids—for the treatment of severe active ANCA-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis). By blocking C5aR1, avacopan inhibits C5a-mediated neutrophil activation and migration, which are central to the pathogenesis of vasculitis. This combination regimen was specifically evaluated in the Phase 2 CLASSIC trial to assess the safety and efficacy of adding avacopan to standard-of-care regimens, with the goal of maintaining disease control while potentially reducing high-dose glucocorticoid exposure.
- Brand names
- Tavneos
- Other names
- CCX168 + cyclophosphamide + rituximab + glucocorticoids
02
Targets
Beyond the preview
Go deeper on avacopan + cyclophosphamide + rituximab + glucocorticoids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on avacopan + cyclophosphamide + rituximab + glucocorticoids.